Professor of Epidemiology (Microbial Diseases) and of Infectious Diseases at Yale School of Public Health
Ivermectin Does Not Reach Primary Endpoint in Burkina Faso Malaria Trial
Sunil Parikh, MD, MPH, discusses the trial’s findings, noting no significant difference in malaria incidence (1.78 vs 1.84 cases per 100 person-weeks).
Read More
Insights from Phase 3 Trial in Burkina Faso on Ivermectin’s Role in Malaria Control
Sunil Parikh, MD, MPH, discussed how challenges like drug resistance and the limitations of current methods hindered ivermectin’s effectiveness in reducing malaria incidence.